<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00924807</url>
  </required_header>
  <id_info>
    <org_study_id>IRB# 004-08</org_study_id>
    <secondary_id>SR06-959</secondary_id>
    <nct_id>NCT00924807</nct_id>
  </id_info>
  <brief_title>Safety Study of Sorafenib With Androgen Deprivation and Radiotherapy to Treat Prostate Cancer</brief_title>
  <official_title>Phase I/II Study of Sorafenib Concurrent With Androgen Deprivation and Radiotherapy in the Treatment of Intermediate- and High-Risk Localized Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Beth Israel Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety of a new drug- sorafenib, which is to be
      administered at the same time as standard treatment, which includes hormonal therapy and
      external beam radiotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Leuprolide acetate (a luteinizing hormone releasing hormone (LHRH) agonist) and Bicalutamide
      (an anti-androgen) are hormonal agents which are commonly used to reduce testosterone blood
      level for prostate cancer treatment. Intensity modulated external beam radiotherapy is a
      standard treatment for localized prostate cancer. Previous studies have shown that combining
      hormonal therapy and radiation is more effective than radiation alone. Unfortunately,
      significant percentages (50-75%) of patients still relapse. Sorafenib reduces the growth of
      cancer cells and has proven effective in the treatment of solid tumors including kidney and
      liver cancer. This drug is approved by the FDA for treatment kidney and liver cancer. The
      study investigators believe that adding sorafenib to standard treatment, comprising hormonal
      therapy and radiation, might be more effective then standard hormonal therapy.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor closed the trial
  </why_stopped>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the Safety and Maximally Tolerated Dose of Sorafenib Administered Concurrently With Radiotherapy in the Treatment of Intermediate- and High-risk Localized Prostate Cancer.</measure>
    <time_frame>Day 29 and every 2 weeks</time_frame>
    <description>Data of zero (&quot;0&quot;) participants were analyzed due to lack of funding and prematurely terminating the study by sponsor. All subjects are following up in the clinic off the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biochemical Disease-free Survival</measure>
    <time_frame>after 9 months</time_frame>
    <description>Data of zero (&quot;0&quot;) participants were analyzed due to lack of funding and prematurely terminating the study by sponsor. All subjects are following up in the clinic off the study.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Androgen Depr, Radiotherapy, Sorafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Everyone will receive Leuprolide acetate, Bicalutamide,Sorafenib and radiotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leuprolide acetate, Bicalutamide, Sorafenib</intervention_name>
    <description>Leuprolide acetate - depot, Bicalutamide 50 mg, Sorafenib 400mg</description>
    <arm_group_label>Androgen Depr, Radiotherapy, Sorafenib</arm_group_label>
    <other_name>Leuprolide acetate</other_name>
    <other_name>Bicalutamide</other_name>
    <other_name>Sorafenib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have histologically confirmed intermediate or high risk prostate
             adenocarcinoma. Intermediate risk disease comprises T2b/c tumors, Gleason 7 histology,
             or PSA 10-20. High risk tumors comprise T3-4, Gleason 8 or higher histology, or PSA
             greater than 20.

          -  Age &gt; 18 years.

          -  Life expectancy of greater than 5 years.

          -  Patients must have normal organ and marrow function.

          -  No pelvic lymph node metastases based on pelvic CT scan or MRI.

          -  No bone metastasis. A whole body bone scan is required to rule out metastatic disease.

        Exclusion Criteria:

          -  Any previous, radiotherapy, or chemotherapy, or more than 4 weeks of androgen
             deprivation hormonal therapy for the treatment of prostate adenocarcinoma.

          -  Patients may not be receiving any other investigational agents.

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to sorafenib or other agents used in this study.

          -  Known human immunodeficiency virus (HIV) infection or chronic Hepatitis B or C.

          -  Patients receiving anti-coagulation treatment with an agent such as warfarin or
             heparin will not be allowed to participate.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seth Cohen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Luke's-Roosevelt Hospital Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St.Luke's-Roosevelt Hospital Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2009</study_first_submitted>
  <study_first_submitted_qc>June 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2009</study_first_posted>
  <results_first_submitted>January 13, 2015</results_first_submitted>
  <results_first_submitted_qc>March 4, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 17, 2015</results_first_posted>
  <last_update_submitted>March 4, 2015</last_update_submitted>
  <last_update_submitted_qc>March 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate Cancer</keyword>
  <keyword>Combined Androgen Blockade</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Sorafenib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Bicalutamide</mesh_term>
    <mesh_term>Leuprolide</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Androgens</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Androgen Depr, Radiotherapy, Sorafenib</title>
          <description>Everyone will receive Leuprolide acetate, Bicalutamide,Sorafenib and radiotherapy.
Leuprolide acetate, Bicalutamide, Sorafenib: Leuprolide acetate - depot, Bicalutamide 50 mg, Sorafenib 400mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Androgen Depr, Radiotherapy, Sorafenib</title>
          <description>Everyone will receive Leuprolide acetate, Bicalutamide,Sorafenib and radiotherapy.
Leuprolide acetate, Bicalutamide, Sorafenib: Leuprolide acetate - depot, Bicalutamide 50 mg, Sorafenib 400mg</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.25" lower_limit="61" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gleason 7 histology, or PSA 10-20</title>
          <description>Prostate cancers are commonly graded using Gleason score or pattern. Gleason grading is based on a 5-component system, based on 5 histologic patterns.
Cancers with a Gleason score of 7 may be called moderately differentiated or intermediate grade.
Prostate-Specific Antigen (PSA) a protein that is produced by the prostate gland. The higher a manâ€™s PSA level, the more likely it is that he has prostate cancer. Most doctors considered PSA levels of 4.0 ng/mL and lower as normal.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Determine the Safety and Maximally Tolerated Dose of Sorafenib Administered Concurrently With Radiotherapy in the Treatment of Intermediate- and High-risk Localized Prostate Cancer.</title>
        <description>Data of zero (&quot;0&quot;) participants were analyzed due to lack of funding and prematurely terminating the study by sponsor. All subjects are following up in the clinic off the study.</description>
        <time_frame>Day 29 and every 2 weeks</time_frame>
        <population>Data of zero (&quot;0&quot;) participants were analyzed due to lack of funding and prematurely terminating the study by sponsor. All subjects are following up in the clinic off the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Androgen Depr, Radiotherapy, Sorafenib</title>
            <description>Everyone will receive Leuprolide acetate, Bicalutamide,Sorafenib and radiotherapy.
Leuprolide acetate, Bicalutamide, Sorafenib: Leuprolide acetate - depot, Bicalutamide 50 mg, Sorafenib 400mg</description>
          </group>
        </group_list>
        <measure>
          <title>Determine the Safety and Maximally Tolerated Dose of Sorafenib Administered Concurrently With Radiotherapy in the Treatment of Intermediate- and High-risk Localized Prostate Cancer.</title>
          <description>Data of zero (&quot;0&quot;) participants were analyzed due to lack of funding and prematurely terminating the study by sponsor. All subjects are following up in the clinic off the study.</description>
          <population>Data of zero (&quot;0&quot;) participants were analyzed due to lack of funding and prematurely terminating the study by sponsor. All subjects are following up in the clinic off the study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biochemical Disease-free Survival</title>
        <description>Data of zero (&quot;0&quot;) participants were analyzed due to lack of funding and prematurely terminating the study by sponsor. All subjects are following up in the clinic off the study.</description>
        <time_frame>after 9 months</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>18 months</time_frame>
      <desc>Adverse Events were assessed by regular investigator assessment, regular laboratory testing</desc>
      <group_list>
        <group group_id="E1">
          <title>Androgen Depr, Radiotherapy, Sorafenib</title>
          <description>Everyone will receive Leuprolide acetate, Bicalutamide,Sorafenib and radiotherapy.
Leuprolide acetate, Bicalutamide, Sorafenib: Leuprolide acetate - depot, Bicalutamide 50 mg, Sorafenib 400mg</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>NCI-CTC version 3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular-Amaurosis fugax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Proctitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary frequency/urgency</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>dysuria</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hand-and-foot syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Data of zero (&quot;0&quot;) participants were analyzed due to lack of funding and prematurely terminating the study by sponsor. All subjects are following up in the clinic off the study. Early termination leading to small number of subjects analyzed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Seth Cohen, MD</name_or_title>
      <organization>St. Luke's Roosevelt Hospital Center</organization>
      <phone>212-523-7289</phone>
      <email>secohen@chpnet.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

